SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions,
– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an ORR of 47% and a clinical benefit rate of 82% – – 50% CR rate and 75% ORR observed in AITL patients
SAN DIEGO , May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track – – Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA and ICML next month – – Data from ongoing Phase 2 trial of tipifarnib in HRAS mutant HNSCC and other
SAN DIEGO , April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2019 financial results after the close of U.S.
– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – – Pre-treatment tumor CXCL12 expression identified as a potential biomarker of clinical benefit in patients
SAN DIEGO , March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway – – Data from three ongoing Phase 2 trials of tipifarnib anticipated this year – – Third drug candidate menin-MLL inhibitor KO-539 poised to enter clinic next quarter – – $179 million in cash, cash equivalents and investments
– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in genes such as NPM1 – – Phase 1 clinical trial in relapsed or refractory AML expected to initiate next
SAN DIEGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2018 financial results after the close of
